Clinical Trials
37 trialsNCT01013961 2023-06-28
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00983528 2020-08-12
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
University of California, San Diego
Phase 1/2 Terminated
NCT00578292 2020-05-01
THALLO
Baylor College of Medicine
Phase NA Terminated
NCT01596699 2020-02-26
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
University of California, San Francisco
Phase 2 Terminated
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00801931 2019-03-27
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
Phase 1/2 Terminated
NCT03132584 2019-01-14
Cyclophosphamide and Alemtuzumab In Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT00038883 2018-11-07
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00626626 2018-04-25
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT02701517 2017-12-29
Cyclosporine Plus Methotrexate or Alemtuzumab
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Terminated
NCT00416884 2017-09-27
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02653196 2017-08-17
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
Montefiore Medical Center
Phase EARLY_PHASE1 Terminated
NCT00555048 2017-05-24
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01191749 2017-05-09
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00698685 2017-03-31
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
University of Arizona
Phase 2 Terminated
NCT00637390 2016-12-02
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00058825 2016-11-07
HIMSUM
Baylor College of Medicine
Phase 1/2 Terminated
NCT00579111 2016-05-04
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Phase 1/2 Terminated
NCT00578539 2016-04-22
REGALE
Baylor College of Medicine
Phase NA Terminated
NCT00578903 2016-04-22
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Baylor College of Medicine
Phase 2 Terminated
NCT01518153 2016-03-17
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00587847 2015-10-15
Campath Maintenance in Chronic Lymphocytic Leukemia
Northwell Health
Phase NA Terminated
NCT00871546 2015-08-07
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00771602 2015-06-23
Alemtuzumab + Rituximab Consolidation in CLL
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00262925 2015-05-05
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00077961 2015-03-26
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Sanofi
Phase 1/2 Terminated
NCT00051701 2015-03-05
Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
Sanofi
Phase 1/2 Terminated
NCT00781781 2015-02-04
Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
CABYC
Phase 2 Terminated
NCT00943293 2014-03-17
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
University of Chicago
Phase 1 Terminated
NCT00113048 2014-02-05
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Sanofi
Phase 1 Terminated
NCT00818961 2013-12-18
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Northside Hospital, Inc.
Phase 2 Terminated
NCT00836043 2013-12-03
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
Sanofi
Terminated
NCT00947388 2013-08-22
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00069992 2012-10-10
MPDMDSBMT
Baylor College of Medicine
Phase 2 Terminated
NCT00453193 2012-08-07
Alemtuzumab and Pentostatin In T-cell Neoplasms
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00505921 2011-11-16
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00441025 2009-06-25
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
Mahidol University
Phase 2 Terminated